KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Leases (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 14 years of Current Leases data on record, last reported at $614000.0 in Q4 2025.

  • For Q4 2025, Current Leases rose 115.44% year-over-year to $614000.0; the TTM value through Dec 2025 reached $614000.0, up 115.44%, while the annual FY2025 figure was $614000.0, 115.44% up from the prior year.
  • Current Leases reached $614000.0 in Q4 2025 per RIGL's latest filing, up from $594000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $9.9 million in Q4 2021 and bottomed at $285000.0 in Q4 2024.
  • Average Current Leases over 5 years is $3.1 million, with a median of $682500.0 recorded in 2023.
  • Peak YoY movement for Current Leases: plummeted 94.59% in 2023, then soared 115.44% in 2025.
  • A 5-year view of Current Leases shows it stood at $9.9 million in 2021, then crashed by 88.55% to $1.1 million in 2022, then tumbled by 38.92% to $692000.0 in 2023, then plummeted by 58.82% to $285000.0 in 2024, then skyrocketed by 115.44% to $614000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $614000.0 in Q4 2025, $594000.0 in Q3 2025, and $517000.0 in Q2 2025.